ICER: Price Hikes Lacking Clinical Evidence Cost Govt. $1.2B In 2019

Drug makers hiked net prices on seven drugs, without clinical evidence to support their higher prices, that cost taxpayers an additional $1.2B in 2019, according to the Institute for Clinical and Economic Review . The seven drugs are Enbrel, Invega Sustenna, Xifaxan, Orencia, Tecfidera, Humira and Vimpat. Drug makers often complain that reports of price increases don’t account for the proprietary rebates that drug companies provide pharmaceutical benefit managers in return for good formulary placement. However, ICER’s $1.2 billion figure...